Quantcast

Latest Plexxikon Stories

2010-08-26 14:00:17

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas, appear in the August 26 New England Journal of Medicine. "Metastatic melanoma has a devastating prognosis and is one of the top causes of cancer death in young patients," says Keith...

2010-06-15 15:45:30

Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma. The compound also showed partial or complete tumor regression and improved survival in a dose-dependent manner in preclinical efficacy models in rodents, without associated toxicity. BRAF mutations are found in about 8...

2010-02-24 05:00:00

CARLSBAD, Calif., Feb. 24 /PRNewswire/ -- AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has launched an expanded test panel to detect 17 B-RAF mutations for research use to enhance the understanding of B-RAF mutations. The featured four-part series in The New York Times, this week focuses on the importance of B-RAF mutations and the next generation of cancer therapies. "We congratulate Plexxikon and Roche on the dramatic success of...

2009-09-08 09:07:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Small Molecule Kinase Inhibitors http://www.reportlinker.com/p0131227/Small-Molecule-Kinase-Inhibitors.html This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others. Annual forecasts are provided for the...

2009-06-03 10:38:53

An early-stage clinical trial of a new cancer drug could lead to the creation of effective melanoma drugs, researchers at a meeting in Orlando, Fla.,said. The Wall Street Journal said Wednesday the study presented at the American Society of Clinical Oncology's annual meeting showed a drug called PLX4032 was effectively used to shrink tumors in nine of 16 study patients. All of the patients used in the study had malignant skin cancer but the drug treatment was only effective in those patients...

2008-10-03 09:00:37

INDIANAPOLIS, Ind. and LAWRENCE, Kan., Oct. 3 /PRNewswire-FirstCall/ -- Eli Lilly and Company and privately-held Deciphera Pharmaceuticals, LLC today announced that the two companies have entered into a collaboration and worldwide licensing agreement related to Deciphera's preclinical B-Raf kinase inhibitor program for the study of potential oncology therapeutics. The collaboration will apply Deciphera's phylomechanics discovery platform, a unique, proprietary approach to kinase inhibitor...

2008-09-04 09:00:08

US-based drug discovery and development company Plexxikon has started a Phase I human clinical trial for PLX5568, a novel kinase inhibitor targeted for the treatment of at least two major indications with unmet medical needs pain as well as polycystic kidney disease. Dosing has been completed in the first cohort of healthy volunteer subjects in the single ascending dose, double-blind, placebo-controlled trial, which will enroll approximately 30 subjects. This study will be followed by a...

2008-08-06 18:00:38

Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that it has acquired from Roche the exclusive development rights for the clinical-stage compound romazarit. Ore Pharmaceuticals had previously identified potentially novel therapeutic uses for romazarit in metabolic diseases and subsequently observed a lowering of lipids, weight, and glucose levels in in vivo testing. The Company filed recently for patent protection regarding the use of the compound for treatment of metabolic diseases....


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related